Eravacycline
drugOn this page
Also known as EravaciclinaTP-434Xerava
Summary
Eravacycline (CHEMBL1951095) is an approved small molecule (ATC J01AA13); indicated across 5 conditions including bacterial infectious disease and urinary tract infection.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J01AA13
- Indications: 5 conditions
- Clinical trials: 13
- Chemistry: 558.6 Da · C27H31FN4O8
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1951095 |
| Name | Eravacycline |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 54726192 |
| ATC | J01AA13 |
| Molecular formula | C27H31FN4O8 |
| Molecular weight | 558.6 |
| InChIKey | AKLMFDDQCHURPW-ISIOAQNYSA-N |
SMILES: CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=C(C(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)NC(=O)CN5CCCC5)F
IUPAC name: (4S,4aS,5aR,12aR)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
Also known as: Eravaciclina, Eravacycline, TP-434, Tp-434, Xerava, ERAVACYCLINE
Parent form; salt/anhydrous children: CHEMBL2219414
Patent coverage: 310 distinct patent families (672 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Bacterial 70S ribosome.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P02358 | 6.21 | IC50 | 620 | nM | CHEMBL_ACT_8036358 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| bacterial infectious disease | 4 | MONDO:0005113 | EFO:0000771 |
| urinary tract infection | 3 | MONDO:0100338 | EFO:0003103 |
| chronic kidney disease | 1 | MONDO:0005300 | EFO:0003884 |
| liver disorder | 1 | MONDO:0005154 | EFO:0001421 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 13.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 4 |
| PHASE1 | 3 |
| PHASE4 | 2 |
| PHASE2 | 2 |
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06440304 | PHASE4 | RECRUITING | Therapeutic Options for CRAB |
| NCT07004049 | PHASE4 | RECRUITING | Optimising TREATment for Severe Gram-Negative Bacterial Infections |
| NCT01844856 | PHASE3 | COMPLETED | Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections |
| NCT01978938 | PHASE3 | COMPLETED | Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections |
| NCT02784704 | PHASE3 | COMPLETED | Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections |
| NCT03032510 | PHASE3 | COMPLETED | Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections |
| NCT05537896 | PHASE2 | RECRUITING | Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia |
| NCT01265784 | PHASE2 | COMPLETED | Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections |
| NCT02135276 | PHASE1 | COMPLETED | A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects |
| NCT02135302 | PHASE1 | COMPLETED | A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects |
| NCT03696550 | PHASE1 | COMPLETED | A Safety and PK Study of IV Eravacycline |
| NCT06223100 | Not specified | UNKNOWN | Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection |
| NCT06282835 | Not specified | UNKNOWN | Eravacycline Combination Therapy for MRAB |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).